Researchers develop nicotinamide N-methyl transferase inhibitor to block ovarian cancer tumor growth

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.

June 27, 2025

Vol.51 No.25

Clinical Roundup

Mayo Clinic researchers use biobanking tissue to better characterize ovarian cancer origins

Little is known about what causes ovarian cancer, and there is no way to detect it early. Now, an accidental finding in a 22-year-old patient has given Mayo Clinic researchers a new lead.

June 27, 2025

Vol.51 No.25

Drugs & Targets

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

FDA has approved Avmapki Fakzynja Co-Pack (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who received prior systemic therapy. Avmapki Fakzynja Co-Pack is the first and only FDA-approved medicine for this disease.

May 23, 2025

Vol.51 No.20

Drugs & Targets

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

May 09, 2025

Vol.51 No.18

Clinical Roundup

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Physicians at Tampa General Hospital and USF Health Morsani College of Medicine conducted a multicenter, retrospective cohort study and found that a highly specialized treatment—heated intraperitoneal chemotherapy delivered directly into the abdominal cavity, is associated with longer survival for women with metastatic epithelial ovarian cancer.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Researchers have identified a “master regulator” gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.

April 04, 2025

Vol.51 No.13

Researchers develop nicotinamide N-methyl transferase inhibitor to block ovarian cancer tumor growth

YOU MAY BE INTERESTED IN

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

Mayo Clinic researchers use biobanking tissue to better characterize ovarian cancer origins

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Renew today!

Subscriber content

Never miss an issue!

Login